对GLP-1受体激活剂和西塔格利平因在糖尿病老鼠心脏中的长期反应
Esra Akcabag1, Zinnet Sevval Aksoyalp2, Feride Oner1
1Department of Pharmacology, Akdeniz University Faculty of Medicine, Antalya, Turkey.
Journal of cardiovascular pharmacology
|March 28, 2024
概括
葡萄糖类-1受体激动剂 (GLP-1RA) 和西塔格利平素会影响糖尿病老鼠心房中的心率. GLP-1RA通过特定的受体和途径起作用,而西塔格利普丁则通过特定的受体和途径起作用.
科学领域:
- 心血管药理学心血管药理学
- 内分泌学和新陈代谢
背景情况:
- 2型糖尿病 (T2DM) 显著增加心血管疾病 (CVD) 的风险.
- 了解抗糖尿病药物的心血管影响对于患者护理至关重要.
- 包括GLP-1受体激活剂 (GLP-1RA) 在内的基于因克雷丁的疗法,被广泛用于T2DM管理.
研究的目的:
- 为了研究GLP-1RA和西塔利普丁对隔离的老鼠心房中的心跳率的影响.
- 探索这些心血管效应所涉及的潜在机制和信号通路.
- 在控制和糖尿病条件下比较这些抗糖尿病药物的慢性反应.
主要方法:
- 从对照组和糖尿病大鼠中分离出的心房被用来评估殴打率.
- 实验涉及单疗法和与各种抗糖尿病药物 (甲福明,皮奥格利塔,格利梅皮里德) 联合治疗.
- 特定的途径抑制剂 (例如,exendin (9-39),氧化合成酶抑制剂,环氧化原酶抑制剂) 用于阐明机制.
主要成果:
- GLP-1 RAs (GLP-1 (7-36),GLP-1 (9-36),exendin-4 (1-39)) 在对照和糖尿病老鼠心房中增加了殴打率.
- 西塔格利普丁仅在糖尿病老鼠心房中表现出长期营养作用.
- GLP-1 RA反应被埃森丁 (9-39),氧化和环氧化原酶途径阻断,但不是通道抑制剂或活性氧物种.
结论:
- GLP-1 RAs通过GLP-1受体,氧化和循环氧化酶通路对隔离的老鼠心房产生积极的时效效应.
- 西塔格利普丁表现出一种独特的作用机制,特别是在糖尿病环境中影响心率.
- 这些发现有助于了解糖尿病中基于因克雷丁的治疗方法的心血管安全性和机制.
相关概念视频
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K


